Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 801–900 of 1,024
Wang, K., Li, L., Fu, L., Yuan, Y., Dai, H., Tianjin, Z., Zhou, Y., & Yuan, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00140 · Cited by 78
“…or epigenetic changes in the occurrence of cancer, as well as promising biomarkers Frontiers in Pharmacology | www.frontiersin.org 7 March 2019 | Volume 10 | Article 140 for cancer diagnosis, treatment, and prognosis (Kulasingam and Diamandis, 2008; Cancer Genome Atlas Research and Network, 2014).”
BackgroundPerioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions
Petrillo, A., Pompella, L., Tirino, G., Pappalardo, A., Laterza, M. M., Caterino, M., Orditura, M., Ciardiello, F., Lieto, E., Galizia, G., et al. (2019) · Cancers · doi:10.3390/cancers11030399 · Cited by 81
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 76
von Loga, K., Woolston, A., Punta, M., Barber, L. J., Griffiths, B. L., Semiannikova, M., Spain, G., Challoner, B. R., Fenwick, K., Simon, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13915-7 · Cited by 82
Diagnosis of digestive system tumours
Washington, M. K., Goldberg, R. M., Chang, G. J., Limburg, P. J., Lam, A. K.-Y., Salto‐Tellez, M., Arends, M. J., Nagtegaal, I. D., Klimstra, D. S., Rugge, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33210 · Cited by 87
Leong, M. M., & Lung, M. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629780 · Cited by 78
Wang, J., Li, R., Cao, Y., Gu, Y., Fang, H., Fei, Y., Lv, K., He, X., Lin, C., Liu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23356-w · Cited by 78
Chen, Y., Sun, Z., Chen, W., Liu, C., Chai, R., Ding, J., Liu, W., Feng, X., Zhou, J. W., Shen, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685992 · Cited by 84
Moon, C. S., Moon, D., & Kang, S. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.782829 · Cited by 82
Guo, T., Tang, X., Gao, X.-Y., Zhou, Y., Jin, B., Deng, Z.-Q., Hu, Y., Xing, X., Li, Z., & Ji, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01684-9 · Cited by 78
Epstein-Barr virus infection: the micro and macro worlds
Huang, W., Bai, L., & Tang, H. (2023) · Virology Journal · doi:10.1186/s12985-023-02187-9 · Cited by 84
Marquitz, A. R., Mathur, A., Edwards, R. H., & Raab‐Traub, N. (2015) · Journal of Virology · doi:10.1128/jvi.01492-15 · Cited by 72
Dong, M., Wang, H.-Y., Zhao, X., Chen, J., Zhang, Y.-W., Huang, Y. J., Xue, L., Li, H., Du, H., Wu, X.-Y., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.02.007 · Cited by 77
Immunotherapy in Gastrointestinal Cancers
Procaccio, L., Schirripa, M., Fassan, M., Vecchione, L., Bergamo, F., Prete, A. A., Intini, R., Manai, C., Dadduzio, V., Boscolo, A., et al. (2017) · BioMed Research International · doi:10.1155/2017/4346576 · Cited by 89
Pereira, M. A., Ramos, M. F. K. P., Faraj, S. F., Dias, A. R., Yagi, O. K., Zilberstein, B., Cecconello, I., Alves, V. A. F., de Mello, E. S., & Ribeiro, U. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25022 · Cited by 77
Nagahashi, M., Wakai, T., Shimada, Y., Ichikawa, H., Kameyama, H., Kobayashi, T., Sakata, J., Yagi, R., Sato, N., Kitagawa, Y., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0387-8 · Cited by 81
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma
Nagaraja, A. K., Kikuchi, O., & Bass, A. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0487 · Cited by 81
Early stage gastric adenocarcinoma: clinical and molecular landscapes
Hirata, Y., Noorani, A., Song, S., Wang, L., & Ajani, J. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00767-w · Cited by 89
Sunakawa, Y., & Lenz, H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0331-y · Cited by 84
Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer
Lim, B., Kim, J.-H., Kim, M., & Kim, S.-Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1190 · Cited by 76
Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease
Smolka, A. J., & Schubert, M. L. (2017) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-50520-6_10 · Cited by 88
Sanjeevaiah, A. R., Cheedella, N. K. S., Hester, C. A., & Porembka, M. R. (2018) · Journal of Oncology Practice · doi:10.1200/jop.17.00025 · Cited by 83
Detecting viral sequences in NGS data
Cantalupo, P. G., & Pipas, J. M. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.010 · Cited by 85
van der Kaaij, R. T., Koemans, W. J., van Putten, M., Snæbjörnsson, P., Luijten, J. C. H. B. M., van Dieren, J. M., Cats, A., Lemmens, V. E. P. P., Verhoeven, R. H. A., & van Sandick, J. W. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.017 · Cited by 80
Molecular Testing for Gastrointestinal Cancer
Lee, H. S., Kim, W. H., Kwak, Y., Koh, J., Bae, J. M., Kim, K., Chang, M. S., Han, H. S., Kim, J. M., Kim, H. W., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.01.24 · Cited by 73
The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond
Schulz, C., Schütte, K., Mayerle, J. V., & Malfertheiner, P. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819894062 · Cited by 80
Kubota, Y., Kawazoe, A., Sasaki, A., Mishima, S., Sawada, K., Nakamura, Y., Kotani, D., Kuboki, Y., Taniguchi, H., Kojima, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0075 · Cited by 75
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Bartolomeo, M. D., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H. C., Muro, K., Cutsem, E. V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.803 · Cited by 78
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 81
“Genetic instability caused by MSI-H/dMMR leads to the accumulation of thousands of mutations and single-nucleotide variants (SNVs) through processes such as DNA polymerase slip-page and unequal crossing over [16, 106, 107], creating a hypermutator phenotype [2, 3, 23].”
BackgroundInfluentialOu, L., Liu, H., Peng, C., Zou, Y., Jia, J., Li, H., Feng, Z., Zhang, G., & Yao, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37046 · Cited by 84
Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma
Gulley, M. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.93 · Cited by 71
Myant, K., Cammareri, P., Hodder, M. C., Wills, J. C., von Kriegsheim, A., Győrffy, B., Rashid, M., Polo, S., Maspero, E., Vaughan, L. S., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606684 · Cited by 80
Till, J. E., Yoon, C., Kim, B., Roby, K. C., Addai, P., Jonokuchi, E., Tang, L. H., Yoon, S. S., & Ryeom, S. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0061 · Cited by 75
“The tumor suppressor p53 (TP53) is altered in about 50% of GAs, with these alterations more common in intestinal than diffuse tumors (6,7).”
Nasopharyngeal carcinoma super-enhancer–driven ETV6 correlates with prognosis
Ke, L., Zhou, H., Wang, C., Xiong, G., Xiang, Y., Ling, Y., Khabir, A., Tsao, G. S., Zeng, Y., Zeng, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705236114 · Cited by 71
Pembrolizumab for Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Joshi, S. S., Maron, S. B., & Catenacci, D. V. T. (2017) · Future Oncology · doi:10.2217/fon-2017-0436 · Cited by 76
Hashimoto, T., Kurokawa, Y., Takahashi, T., Miyazaki, Y., Tanaka, K., Makino, T., Yamasaki, M., Nakajima, K., Ikeda, J.-I., Mori, M., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00918-4 · Cited by 72
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Van Allen, E. M., Golay, H. G., Liu, Y., Koyama, S., Wong, K., Taylor-Weiner, A., Giannakis, M., Harden, M., Rojas-Rudilla, V., Chevalier, A., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0024 · Cited by 69
Catenacci, D. V. T., Tesfaye, A. A., Tejani, M. A., Cheung, E. M., Eisenberg, P. D., Scott, A. J., Eng, C., Hnatyszyn, J. H., Marina, N. M., Powers, J. M., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0141 · Cited by 71
Kwan, S., Sheel, A., Song, C., Zhang, X., Jiang, T., Dang, H. T., Cao, Y., Özata, D. M., Mou, H., Yin, H., et al. (2019) · Hepatology · doi:10.1002/hep.30807 · Cited by 79
Mitani, S., & Kawakami, H. (2020) · Cancers · doi:10.3390/cancers12020400 · Cited by 73
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 73
miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer
Miliotis, C., & Slack, F. J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.037 · Cited by 69
Hirabayashi, M., Georges, D., Clifford, G. M., & de Martel, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.07.042 · Cited by 78
OpenPBTA: The Open Pediatric Brain Tumor Atlas
Shapiro, J. A., Gaonkar, K. S., Spielman, S. J., Savonen, C., Bethell, C. J., Jin, R., Rathi, K. S., Zhu, Y., Egolf, L. E., Farrow, B., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100340 · Cited by 87
“Interestingly, we found that hypermutant HGGs universally displayed TP53 dysregulation, unlike adult cancers like colorectal cancer and gastric adenocarcinoma, where TP53 dysregulation in hypermutated tumors is less common.(65,66) Furthermore, high TP53 scores were a significant prognostic marker for poor overall surv…”
BackgroundSingle-Cell RNA Sequencing: Technological Progress and Biomedical Application in Cancer Research
Xu, C., Zheng, Y., & Xu, K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00777-0 · Cited by 85
Divergent viral presentation among human tumors and adjacent normal tissues
Cao, S., Wendl, M. C., Wyczalkowski, M. A., Wylie, K. M., Ye, K., Jayasinghe, R. G., Xie, M., Wu, S., Niu, B., Grubb, R. L., et al. (2016) · Scientific Reports · doi:10.1038/srep28294 · Cited by 77
Guo, L., Li, W., Zhu, X., Ling, Y., Qiu, T., Lin, D., Fang, Y., Yang, H., & Ying, J. (2016) · SpringerPlus · doi:10.1186/s40064-016-2513-x · Cited by 72
Ma, J., Li, J., Hao, Y., Nie, Y., Li, Z., Qian, M., Liang, Q., Yu, J. Q., Zeng, M., & Wu, K. (2017) · Oncotarget · doi:10.18632/oncotarget.17945 · Cited by 74
The Microenvironment in Epstein–Barr Virus-Associated Malignancies
Tan, G. W., Visser, L., Tan, L., van den Berg, A., & Diepstra, A. (2018) · Pathogens · doi:10.3390/pathogens7020040 · Cited by 68
Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells
Fenderico, N., van Scherpenzeel, R. C., Goldflam, M., Proverbio, D., Jordens, I., Kralj, T., Stryeck, S., Bass, T. Z., Hermans, G., Ullman, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08172-z · Cited by 67
Eso, Y., & Seno, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820948773 · Cited by 72
The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis
Stanland, L. J., & Luftig, M. A. (2020) · Viruses · doi:10.3390/v12111222 · Cited by 71
The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects
Yuan, W., Shi, Y., Dai, S., Deng, M., Zhu, K., Xu, Y., Chen, Z., Zhou, X., Zhang, T., & Song, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05998-8 · Cited by 81
“Recently, TCGA network identified EBVaGC as a distinct subgroup, the activation of immune signaling pathways represents another key characteristic [82].”
Screening and Early Detection of Gastric Cancer
Suh, Y., & Yang, H. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.012 · Cited by 78
Dai, C., Geng, R., Wang, C., Wong, A., Qing, M., Hu, J., Sun, Y. L., Lo, A. W. I., & Li, J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.004 · Cited by 69
Schneider, B. J., Shah, M. A., Klute, K. A., Ocean, A. J., Popa, E., Altorki, N. K., Lieberman, M., Schreiner, A. M., Yantiss, R. K., Christos, P. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1896 · Cited by 70
West, A. C., Tang, K., Tye, H., Yu, L., Deng, N., Najdovska, M., Lin, S. J., Balic, J. J., Okochi‐Takada, E., McGuirk, P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.121 · Cited by 71
MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway
An, L., Nie, P., Chen, M., Tang, Y., Zhang, H., Guan, J., Cao, Z., Hou, C., Wang, W., Zhao, Y., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191817 · Cited by 70
Kanda, T., Furuse, Y., Oshitani, H., & Kiyono, T. (2016) · Journal of Virology · doi:10.1128/jvi.00060-16 · Cited by 75
Yoon, C. J., Chang, M. S., Kim, D. H., Kim, W. K., Koo, B. K., Yun, S., Kim, S., Kim, Y. S., & Woo, J. H. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01059-3 · Cited by 71
Hatano, Y., Ideta, T., Hirata, A., Hatano, K., Tomita, H., Okada, H., Shimizu, M., Tanaka, T., & Hara, A. (2021) · Cancers · doi:10.3390/cancers13112625 · Cited by 77
Molecular Alterations in Gastric Preneoplastic Lesions and Early Gastric Cancer
Battista, S., Ambrosio, M. R., Limarzi, F., Gallo, G., & Saragoni, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136652 · Cited by 71
“In 2014, based on key DNA defects and molecular abnormalities, The Cancer Genome Atlas Consortium (TCGA) divided gastric cancers into Epstein-Barr virus (EBV)-positive, microsatellite instability (MSI), gene stable (GS), and chromosome instability (CIN) types [13].”
BackgroundChow, L. K.-Y., Chung, D. L., Tao, L., Chan, K. F., Tung, S. Y., Ngan, R. K., Ng, W. T., Lee, A. W. M., Yau, C. C., Kwong, D. L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104357 · Cited by 77
Endoscopic Gastric Cancer Screening and Surveillance in High-Risk Groups
Choi, I. J. (2014) · Clinical Endoscopy · doi:10.5946/ce.2014.47.6.497 · Cited by 72
Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer
Böger, C., Warneke, V. S., Behrens, H., Kalthoff, H., Goodman, S. L., Becker, T., & Röcken, C. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0435-2 · Cited by 68
Runx3 at the interface of immunity, inflammation and cancer
Lotem, J., Levanon, D., Negreanu, V., Bauer, O., Hantisteanu, S., Dicken, J., & Groner, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.004 · Cited by 79
Rosa, S. D., Sahnane, N., Tibiletti, M. G., Magnoli, F., Vanoli, A., Sessa, F., & Chiaravalli, A. M. (2018) · Cancers · doi:10.3390/cancers10040102 · Cited by 75
Therapeutic Potential of Natural Killer Cells in Gastric Cancer
Du, Y., & Wei, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03095 · Cited by 74
Machlowska, J., Pucułek, M., Sitarz, M., Terlecki, P., Maciejewski, R., & Sitarz, R. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188622 · Cited by 71
Jiang, Y., Wang, W., Chen, C., Zhang, X., Zha, X., Lv, W., Xie, J., Huang, W., Sun, Z., Hu, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00340 · Cited by 70
Immune checkpoint inhibitors in the treatment of virus-associated cancers
Gao, P., Lazare, C., Cao, C., Meng, Y., Wu, P., Zhi, W., Lin, S., Wei, J., Huang, X., Xi, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0743-4 · Cited by 69
Xie, Z., Liu, L., Lin, X., Xie, X., Gu, Y., Liu, M., Zhang, J., Ouyang, M., Lizaso, A., Zhang, H., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0391-9 · Cited by 68
PVT1 Long Non-coding RNA in Gastrointestinal Cancer
Martínez‐Barriocanal, Á., Arango, D., & Dopeso, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00038 · Cited by 86
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
Pandey, A., Stawiski, E. W., Durinck, S., Gowda, H., Goldstein, L. D., Barbhuiya, M. A., Schröder, M., Sreenivasamurthy, S. K., Kim, S., Phalke, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17880-4 · Cited by 75
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy
Kawakami, H., & Okamoto, I. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0585-x · Cited by 69
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 76
Cho, J., Lee, J., Bang, H., Kim, S. T., Park, S. H., An, J. Y., Choi, M. G., Lee, J. H., Sohn, T. S., Bae, J. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14519 · Cited by 69
Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer
Pereira‐Marques, J., Ferreira, R. M., Pinto-Ribeiro, I., & Figueiredo, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_366 · Cited by 83
Milano, A. F. (2019) · Journal of Insurance Medicine · doi:10.17849/insm-48-1-1-19.1 · Cited by 66
Organoid model: A new hope for pancreatic cancer treatment?
Chen, H., Zhuo, Q., Zeng, Y., Xu, X., & Ji, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188466 · Cited by 78
Shitara, K., Baba, E., Fujitani, K., Oki, E., Fujii, S., & Yamaguchi, K. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01196-3 · Cited by 75
Molecular classification and prediction in gastric cancer
Lin, X., Zhao, Y., Song, W., & Zhang, B. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.08.001 · Cited by 71
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond
Kelly, C. M., & Janjigian, Y. Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.10 · Cited by 79
Koh, J., Ock, C.-Y., Kim, J. W., Nam, S. K., Kwak, Y., Yun, S., Ahn, S.-H., Park, D. J., Kim, H., Kim, W. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15465 · Cited by 73
Molecular classifications of gastric cancers: Novel insights and possible future applications
Garattini, S. K., Basile, D., Cattaneo, M., Fanotto, V., Ongaro, E., Bonotto, M., Negri, F., Berenato, R., Ermacora, P., Cardellino, G. G., et al. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i5.194 · Cited by 82
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Zhao, D., Klempner, S. J., & Chao, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0737-2 · Cited by 70
Wang, C., & Liang, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-35682-z · Cited by 68
Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
Nakayama, I., Shinozaki, E., Sakata, S., Yamamoto, N., Fujisaki, J., Muramatsu, Y., Hirota, T., Takeuchi, K., Takahashi, S., Yamaguchi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13967 · Cited by 68
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
Jung, M., Yang, Y., McCloskey, J. E., Zaman, M., Vedvyas, Y., Zhang, X., Stefanova, D. I., Gray, K. D., Min, I. M., Zarnegar, R., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.009 · Cited by 68
Suh, Y.-S., Na, D., Lee, J.-S., Chae, J., Kim, E., Jang, G., Lee, J., Min, J., Ock, C.-Y., Kong, S.-H., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004303 · Cited by 67
“CIN type was the most common for both groups, and there was no Epstein–Barr virus type in the EAC-like group.(12) Regarding the ACRG subtypes, the proportion of epithelial-mesenchymal transition (EMT) type was significantly higher in the GCFB-like groups (33.”
BackgroundDuarte, H. O., Rodrigues, J. G., Gomes, C., Hensbergen, P. J., Ederveen, A. L. H., de Ru, A. H., Mereiter, S., Polónia, A., Fernandes, E., Ferreira, J. A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01801-w · Cited by 74
Identification of gastric cancer subtypes based on pathway clustering
Li, L., & Wang, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00186-z · Cited by 72
Epigenetic control of the Epstein-Barr lifecycle
Guo, R., & Gewurz, B. E. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.013 · Cited by 69
Tabernero, J. M., Shen, L., Elimova, E. C., Ku, G. Y., Liu, T., Shitara, K., Lin, X., Boyken, L., Li, H., Grim, J. A., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0595 · Cited by 73
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., & Takayama, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144646 · Cited by 83
Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer
Park, H., Cho, S., Kim, H., Na, D., Han, J. Y., Chae, J., Park, C., Park, O.-K., Min, S., Kang, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507491112 · Cited by 82
Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma
González, R. S., Messing, S. P., Tu, X. M., McMahon, L. A., & Whitney‐Miller, C. L. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.06.003 · Cited by 73
Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1
Patel, O., Dai, W., Mentzel, M., Griffin, M. D. W., Serindoux, J., Gay, Y., Fischer, S., Sterle, S., Kropp, A., Burns, C. J., et al. (2016) · Structure · doi:10.1016/j.str.2016.07.008 · Cited by 64
The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models
Hayakawa, Y., Fox, J. G., & Wang, T. C. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.013 · Cited by 75
Staudacher, J. J., Bauer, J., Jana, A., Tian, J., Carroll, T., Mancinelli, G., Özden, Ö., Krett, N., Guzman, G., Kerr, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05907-8 · Cited by 64
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.